Trial Profile
A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary) ; Rucaparib (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Epirubicin; Paclitaxel; Pemetrexed
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 01 May 2022 Results of population pharmacokinetics model Study 1014 (NCT01009190), Study 10 (NCT01482715), and ARIEL2 (NCT01891344) published in the Cancer Chemotherapy and Pharmacology
- 18 Mar 2017 Results of population pharmacokinetics of Rucaparib developed from A4991014 (n=35), NCT01482715 (n=124) and NCT01891344 (n=300) and 2 other studies, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 12 Feb 2017 Results published in the British Journal of Cancer.